National Association of Chain Drug Stores (NACDS) expressed its support for postponing the removal of the Universal Product Code (UPC-A) barcode system – scheduled for January 1, 2010. NACDS compliments and supports the Grocery Manufacturers Association’s (GMA) recommendation that the GS1 DataBar system implementation be delayed until January 1, 2011. pharmaceutical innovation
Spherix Incorporated (Nasdaq CM: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, announced positive preliminary results from a Phase 2 clinical trial of its novel compound, Naturlose(R) (D-tagae), in the treatment and management of Type 2 diabetes. The Phase 2 trial is expected to be completed in early 2010. pharmaceutical innovation
Conatus Pharmaceuticals Inc. announced the initiation of a second Phase 2 clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The trial will enroll patients for whom treatment with approved standard of care treatments is not currently advised. Results from an earlier clinical trial in HCV patients who failed standard of care treatment are expected to be reported later this year. pharmaceutical innovation
In the recently completed 12 week Phase IIb clinical trial in 494 patients with type 2 diabetes mellitus (T2DM), ‘Melogliptin’, Glenmark’s investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycemic control in patients with type 2 diabetes mellitus and exhibited excellent safety and tolerability profile. In addition, patients taking Melogliptin experienced low incidence of hypoglycemia and neutral effect on body weight. pharmaceutical innovation
Amazon.com: Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the Pharmaceutical Industry: Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz: BooksAmazon.com: Leading Pharmaceutical Innovation: Trends and Drivers for .
3 Table of Contents Foreword 5 Executive Summary 7 Chapter I Medicines Innovation: 11 Its value and contribution to public health The Value of Medicines Innovation 11 How Much More . IFPMA PHARMACEUTICAL couv
MUNICH—-European Small and Medium-sized biopharmaceutical companies had the opportunity to network with counterparts from the larger pharmaceutical companies at the third edition of the Business Development Conference, organised by the industry associations European Biopharmaceutical Enterprises and BIO Deutschland.BIO Deutschland: Innovative Financing and New Pathways for Coping with the Global Crisis within the European . (Business Wire Finance)
